FDA expands approval of breast cancer drug Kisqali
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA expands approval for drug to treat early-stage breast cancer
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. NBC News' Kathy Park speaks to a woman who took the drug while it was in clinical trials and is now cancer free.
FDA Expands Use of Breast Cancer Drug Kisqali
The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph nodes] disease, is a pivotal moment in improving our approach to care,” said Dr.
FDA expanded their approval on drug cancer drug
First News
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population. The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence,
Cure Today15h
Navigating the ‘Ever-Evolving Trajectory’ of Metastatic Breast Cancer
Through communication and education, patients with metastatic breast cancer may be able to balance treatment with quality of ...
Medscape1d
Mental Health Considerations in Metastatic Breast Cancer: 5 Things to Know
The high prevalence of depression and anxiety among patients with MBC correlates with diminished survival rates and ...
Targeted Oncology15h
Elacestrant-Abemaciclib Combo Shows Promise for Breast Cancer
The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...
WTKR8h
Friends of Norfolk artist diagnosed with breast cancer fulfill her dying wish
Kim Keene was not only a beloved artist, she was a mother and a business owner. She lost her battle with breast cancer, but her friends vow to carry on her mission of helping others.
Medscape20h
Evolving Conversations in HER2+ Oligometastatic Breast Cancer Management
Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic ...
The American Journal of Managed Care3d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
1 Ribociclib is manufactured by Novartis for early breast cancer and advanced or metastatic breast cancer. 2 The approval was supported by the NATALEE (NCT03701334) trial, a randomized, open ...
Oncolytics Biotech Reports Favorable Results For Breast Cancer Study
(RTTNews) - Clinical-stage company Oncolytics Biotech Inc. (ONCY), Thursday announced positive clinical results from BRACELET-1, its randomized Phase 2 study evaluating pelareorep in patients with HR+ ...
Cure Today4d
Enhertu Maintains Quality of Life in Metastatic Breast Cancer Subgroup
Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...